Biologic and Biosimilar medicines are playing an increasingly important role for many patient communities and the safe, effective and consistent use of these medicines is an area of concern for many IPPOSI members.
In addition, the introduction and adoption of biosimilar medicines has the potential to make significant cost savings for the Irish health system, which may result in facilitating greater access for Irish patients to these and other innovative treatments.
The Minister for Health is supporting the development of a National Biosimilar Policy in Ireland. A consultation paper on the National Biosimilar Policy is due to be published in 2017, which will inform any legal changes needed to the Health (Pricing and Supply of Medical Goods) Act 2013.
IPPOSI is conducting a number of initiatives to increase IPPOSI member knowledge and awareness on this topical area, and has plans to input into the development of the national policy for biosimilars.